No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 23,172 | 26,281 | 1,388 | 21,983 | 2,655 | 26,800 | N/A | N/A |
| Operating profit | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | €m | 883 | 1,231 | 781 | 1,825 | 2,329 | 2,640 | N/A | N/A |
| EPS reported | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | €m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | € | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Hannover Rück SE, along with its group entities, offers a broad spectrum of reinsurance products and services worldwide. Operations are structured around two principal segments: Property & Casualty Reinsurance, and Life & Health Reinsurance. Within Property & Casualty Reinsurance, its offerings span traditional property and casualty coverage, facultative arrangements, extensive catastrophe excess-of-loss protection, custom-tailored structured reinsurance, and innovative insurance-linked securities. The company further specializes in risk solutions for agriculture, livestock, bloodstock, aviation, space, marine, and offshore energy industries, in addition to providing coverage for credit, surety, and political risks. Its Life & Health Reinsurance segment encompasses a range of products including group and individual credit life, enhanced annuities, collective life and health schemes, and Takaful reinsurance. It also engineers risk solutions addressing critical illness, disability, general health, longevity, long-term care, mortality, and morbidity. Beyond its core reinsurance activities, the firm delivers diverse financial solutions, such as financing new business ventures, monetizing embedded value, providing reserve and solvency relief, and assisting with the divestiture of non-core operations. Founded in 1966, the company maintains its headquarters in Hanover, Germany. It was formerly known as Hannover Rückversicherung AG before rebranding to Hannover Rück SE in March 2013. Hannover Rück SE functions as a subsidiary of Talanx AG.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Hannover Rück SE (HNR1.DE)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Hannover Rück SE, along with its group entities, offers a broad spectrum of reinsurance products and services worldwide. Operations are structured around two principal segments: Property & Casualty Reinsurance, and Life & Health Reinsurance. Within Property & Casualty Reinsurance, its offerings span traditional property and casualty coverage, facultative arrangements, extensive catastrophe excess-of-loss protection, custom-tailored structured reinsurance, and innovative insurance-linked securities. The company further specializes in risk solutions for agriculture, livestock, bloodstock, aviation, space, marine, and offshore energy industries, in addition to providing coverage for credit, surety, and political risks. Its Life & Health Reinsurance segment encompasses a range of products including group and individual credit life, enhanced annuities, collective life and health schemes, and Takaful reinsurance. It also engineers risk solutions addressing critical illness, disability, general health, longevity, long-term care, mortality, and morbidity. Beyond its core reinsurance activities, the firm delivers diverse financial solutions, such as financing new business ventures, monetizing embedded value, providing reserve and solvency relief, and assisting with the divestiture of non-core operations. Founded in 1966, the company maintains its headquarters in Hanover, Germany. It was formerly known as Hannover Rückversicherung AG before rebranding to Hannover Rück SE in March 2013. Hannover Rück SE functions as a subsidiary of Talanx AG.
